Peptic ulcer classification

Jump to navigation Jump to search

Peptic ulcer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Peptic Ulcer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Upper GI Endoscopy

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Endoscopic management
Surgical management

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

2017 ACG Guidelines for Peptic Ulcer Disease

Guidelines for the Indications to Test for, and to Treat, H. pylori Infection

Guidelines for First line Treatment Strategies of Peptic Ulcer Disease for Providers in North America

Guidlines for factors that predict the successful eradication when treating H. pylori infection

Guidelines to document H. pylori antimicrobial resistance in the North America

Guidelines for evaluation and testing of H. pylori antibiotic resistance

Guidelines for when to test for treatment success after H. pylori eradication therapy

Guidelines for penicillin allergy in patients with H. pylori infection

Guidelines for the salvage therapy

Peptic ulcer classification On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Peptic ulcer classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Peptic ulcer classification

CDC on Peptic ulcer classification

Peptic ulcer classification in the news

Blogs on Peptic ulcer classification

to Hospitals Treating Peptic ulcer

Risk calculators and risk factors for Peptic ulcer classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Peptic ulcer disease may be classified into two types based on the location within the gastrointestinal tract. gastric ulcer and duodenal ulcer. Gastric ulcers are present mostly at lesser curvature of the stomach while Duodenal ulcers are mostly present at the duodenal bulb.

Classification

Peptic ulcer

Peptic ulcer disease may be classified according to location into two subtypes: [1][2]

Classification and prevalences of stigmata of recent hemorrhage of peptic ulcer using endoscopy

Classification and prevalences of stigmata of recent hemorrhage of peptic ulcer using endoscopy*
Stigmata of hemorrhage Forrest classification Prevalence
Active spurting bleeding IA 12%(spurting+oozing)
Active oozing bleeding IB
Non-bleeding visible vessel IIA 8%
Adherent clot IIB 8%
Flat pigmented spot IIC 16%
Clean base III 55%

*Adopted:American college of gasteroenterology[3]

Gastric ulcer

Gastric ulcer is further divided on the basis of location and endoscopic findings:

Johnson classification

  • Gastric ulcer is further classified into 3 subtypes depending upon their location:[4][5][6]
    • Type 1: Ulcer present at the body of stomach without involving duodenum, pylorus or prepyloric region and not associated with hypersecretion of gastric acid
    • Type 2: Ulcer present at the body of stomach combined with duodenum and associated with gastric acid hypersecretion
    • Type 3: Ulcer close to pylorus and associated with gastric acid hypersecretion

Sakita classification

  • Gastric ulcer classification by using endoscopic staging system of Sakita into three stages:[7]
    • Active
    • Healing
    • Scarring
ACTIVE STAGE
A1 Surrounding mucosa is found to be edematously swollen and there is no regenerating epithelium seen on endoscopy
A2 Surrounding mucosa is less edematous, a small amount of regenerating epithelium is seen at the ulcer margin

A red halo in the marginal zone, a white slough circle and converging mucosal folds t the ulcer margin are frequently seen

HEALING STAGE
H1 The white coating is becoming thin and the regenerating epithelium is extending into the ulcer base

The gradient between the ulcer margin and the ulcer floor is becoming flat

The ulcer crater is still evident and the margin of the ulcer is sharp

The diameter of the mucosal defect is about one-half to two thirds that of A1

H2 The defect is smaller than in H1 and the regenerating epithelium covers most of the ulcer floor. The area of white coating is about a quarter to one-third that of A1
SCARRING STAGE
S1 The regenerating epithelium completely covers the floor of the ulcer

The white coating has disappeared

Initially, the regenerating region is markedly red but upon close observation, many capillaries can be seen and this is called ‘‘red scar’’

S2 In several months to a few years, the redness is reduced to the color of the surrounding mucosa and this is called ‘‘white scar’’

References

  1. Belousov AS, Rakitskaia LG, Mamedova LD, Zhakov VP (1989). "[Pathogenesis and classification of peptic ulcer]". Vrach Delo (3): 70–3. PMID 2750129.
  2. Tytgat GN (2011). "Etiopathogenetic principles and peptic ulcer disease classification". Dig Dis. 29 (5): 454–8. doi:10.1159/000331520. PMID 22095009.
  3. "Management of Patients with Ulcer Bleeding | American College of Gastroenterology".
  4. Johnson HD (1965). "Gastric ulcer: classification, blood group characteristics, secretion patterns and pathogenesis". Ann. Surg. 162 (6): 996–1004. PMC 1477018. PMID 5845595.
  5. BARON JH (1963). "AN ASSESSMENT OF THE AUGMENTED HISTAMINE TEST IN THE DIAGNOSIS OF PEPTIC ULCER. CORRELATIONS BETWEEN GASTRIC SECRETION, AGE AND SEX OF PATIENTS, AND SITE AND NATURE OF THE ULCER". Gut. 4: 243–53. PMC 1413442. PMID 14058266.
  6. JOHNSON HD (1955). "The special significance of concomitant gastric and duodenal ulcers". Lancet. 268 (6858): 266–70. PMID 13234346.
  7. Kaneko E, Hoshihara Y, Sakaki N, Harasawa S, Ashida K, Asaka M; et al. (2000). "Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor". J Gastroenterol. 35 (11): 824–31. PMID 11085491.

Template:WikiDoc Sources